{"text": "Intravenous azithromycin-induced ototoxicity.", "entities": [{"start": 12, "end": 24, "label": "DRUG"}, {"start": 33, "end": 44, "label": "ADE"}]}
{"text": "Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation.", "entities": [{"start": 91, "end": 109, "label": "DRUG"}, {"start": 113, "end": 123, "label": "DRUG"}]}
{"text": "Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol.", "entities": [{"start": 84, "end": 102, "label": "DRUG"}, {"start": 14, "end": 34, "label": "ADE"}]}
{"text": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "entities": [{"start": 58, "end": 66, "label": "DRUG"}, {"start": 71, "end": 80, "label": "DRUG"}, {"start": 32, "end": 47, "label": "ADE"}]}
{"text": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "entities": [{"start": 0, "end": 8, "label": "DRUG"}]}
{"text": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "entities": [{"start": 34, "end": 42, "label": "DRUG"}, {"start": 96, "end": 105, "label": "DRUG"}, {"start": 146, "end": 158, "label": "ADE"}, {"start": 163, "end": 182, "label": "ADE"}]}
{"text": "BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem.", "entities": [{"start": 67, "end": 76, "label": "DRUG"}, {"start": 85, "end": 100, "label": "ADE"}, {"start": 104, "end": 120, "label": "ADE"}]}
{"text": "CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects.", "entities": [{"start": 37, "end": 47, "label": "DRUG"}, {"start": 88, "end": 97, "label": "DRUG"}, {"start": 106, "end": 122, "label": "ADE"}, {"start": 157, "end": 181, "label": "ADE"}]}
{"text": "Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.", "entities": [{"start": 17, "end": 31, "label": "DRUG"}]}
{"text": "We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.", "entities": [{"start": 32, "end": 36, "label": "DRUG"}, {"start": 76, "end": 92, "label": "ADE"}, {"start": 94, "end": 117, "label": "ADE"}, {"start": 119, "end": 145, "label": "ADE"}, {"start": 151, "end": 170, "label": "ADE"}]}
{"text": "This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.", "entities": [{"start": 24, "end": 29, "label": "DRUG"}, {"start": 47, "end": 67, "label": "DRUG"}, {"start": 124, "end": 158, "label": "ADE"}]}
{"text": "We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.", "entities": [{"start": 180, "end": 185, "label": "DRUG"}, {"start": 239, "end": 249, "label": "DRUG"}, {"start": 20, "end": 54, "label": "ADE"}]}
{"text": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "entities": [{"start": 37, "end": 45, "label": "DRUG"}]}
{"text": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "entities": [{"start": 79, "end": 87, "label": "DRUG"}, {"start": 50, "end": 65, "label": "ADE"}]}
{"text": "Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.", "entities": [{"start": 30, "end": 51, "label": "DRUG"}]}
{"text": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "entities": [{"start": 111, "end": 120, "label": "DRUG"}, {"start": 145, "end": 156, "label": "DRUG"}, {"start": 56, "end": 73, "label": "ADE"}, {"start": 270, "end": 287, "label": "ADE"}]}
{"text": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "entities": [{"start": 44, "end": 55, "label": "DRUG"}, {"start": 84, "end": 93, "label": "DRUG"}]}
{"text": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "entities": [{"start": 158, "end": 169, "label": "DRUG"}, {"start": 198, "end": 207, "label": "DRUG"}, {"start": 111, "end": 128, "label": "ADE"}]}
{"text": "Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.", "entities": [{"start": 57, "end": 64, "label": "DRUG"}]}
{"text": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.", "entities": [{"start": 79, "end": 91, "label": "DRUG"}, {"start": 14, "end": 37, "label": "ADE"}]}
{"text": "We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.", "entities": [{"start": 77, "end": 90, "label": "ADE"}]}
{"text": "We describe a life threatening side effect of acute epoprostenol infusion (pulmonary edema) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology.", "entities": [{"start": 52, "end": 64, "label": "DRUG"}, {"start": 75, "end": 90, "label": "ADE"}]}
{"text": "A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.", "entities": [{"start": 91, "end": 101, "label": "DRUG"}, {"start": 56, "end": 81, "label": "ADE"}]}
{"text": "Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.", "entities": [{"start": 0, "end": 11, "label": "DRUG"}, {"start": 20, "end": 50, "label": "ADE"}]}
{"text": "The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.", "entities": [{"start": 78, "end": 89, "label": "DRUG"}, {"start": 38, "end": 62, "label": "ADE"}]}
{"text": "This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.", "entities": [{"start": 26, "end": 37, "label": "DRUG"}, {"start": 46, "end": 76, "label": "ADE"}]}
{"text": "Allergic and irritant contact dermatitis to calcipotriol.", "entities": [{"start": 44, "end": 56, "label": "DRUG"}, {"start": 13, "end": 40, "label": "ADE"}]}
{"text": "Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.", "entities": [{"start": 0, "end": 12, "label": "DRUG"}, {"start": 110, "end": 128, "label": "ADE"}]}
{"text": "The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.", "entities": [{"start": 232, "end": 244, "label": "DRUG"}]}
{"text": "Myotonia associated with sarcoidosis: marked exacerbation with pravastatin.", "entities": [{"start": 63, "end": 74, "label": "DRUG"}]}
{"text": "Pravastatin is associated with myotonia in animals.", "entities": [{"start": 0, "end": 11, "label": "DRUG"}, {"start": 31, "end": 39, "label": "ADE"}]}
{"text": "This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans.", "entities": [{"start": 40, "end": 51, "label": "DRUG"}, {"start": 97, "end": 105, "label": "ADE"}, {"start": 171, "end": 179, "label": "ADE"}]}
{"text": "Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.", "entities": [{"start": 20, "end": 27, "label": "DRUG"}, {"start": 49, "end": 61, "label": "ADE"}, {"start": 63, "end": 72, "label": "ADE"}, {"start": 80, "end": 90, "label": "ADE"}, {"start": 97, "end": 128, "label": "ADE"}]}
{"text": "CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole.", "entities": [{"start": 101, "end": 111, "label": "DRUG"}]}
{"text": "Fixed drug eruption in hands caused by omeprazole.", "entities": [{"start": 39, "end": 49, "label": "DRUG"}]}
{"text": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.", "entities": [{"start": 95, "end": 105, "label": "DRUG"}, {"start": 54, "end": 73, "label": "ADE"}]}
{"text": "A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.", "entities": [{"start": 248, "end": 267, "label": "DRUG"}, {"start": 121, "end": 137, "label": "ADE"}, {"start": 142, "end": 150, "label": "ADE"}, {"start": 174, "end": 181, "label": "ADE"}, {"start": 187, "end": 192, "label": "ADE"}]}
{"text": "Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.", "entities": [{"start": 54, "end": 73, "label": "DRUG"}]}
{"text": "We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.", "entities": [{"start": 81, "end": 100, "label": "DRUG"}, {"start": 20, "end": 62, "label": "ADE"}]}
{"text": "CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).", "entities": [{"start": 72, "end": 82, "label": "DRUG"}, {"start": 96, "end": 127, "label": "ADE"}]}
{"text": "DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin.", "entities": [{"start": 12, "end": 22, "label": "DRUG"}, {"start": 75, "end": 88, "label": "ADE"}]}
{"text": "Marked elevation of serum creatine kinase associated with olanzapine therapy.", "entities": [{"start": 58, "end": 68, "label": "DRUG"}, {"start": 7, "end": 41, "label": "ADE"}]}
{"text": "OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy.", "entities": [{"start": 94, "end": 104, "label": "DRUG"}, {"start": 38, "end": 72, "label": "ADE"}]}
{"text": "Diclofenac-associated hepatitis.", "entities": [{"start": 22, "end": 31, "label": "ADE"}]}
{"text": "This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.", "entities": [{"start": 103, "end": 113, "label": "DRUG"}, {"start": 55, "end": 71, "label": "ADE"}]}
{"text": "2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis.", "entities": [{"start": 0, "end": 5, "label": "DRUG"}, {"start": 14, "end": 29, "label": "ADE"}]}
{"text": "One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported.", "entities": [{"start": 37, "end": 44, "label": "DRUG"}, {"start": 12, "end": 20, "label": "ADE"}]}
{"text": "Priapism as a complication of heparin therapy.", "entities": [{"start": 30, "end": 37, "label": "DRUG"}]}
{"text": "The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.", "entities": [{"start": 24, "end": 31, "label": "DRUG"}, {"start": 36, "end": 44, "label": "ADE"}]}
{"text": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "entities": [{"start": 117, "end": 126, "label": "DRUG"}, {"start": 32, "end": 43, "label": "ADE"}, {"start": 48, "end": 63, "label": "ADE"}]}
{"text": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "entities": [{"start": 60, "end": 69, "label": "DRUG"}, {"start": 45, "end": 56, "label": "ADE"}]}
{"text": "Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia.", "entities": [{"start": 41, "end": 64, "label": "DRUG"}]}
{"text": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.", "entities": [{"start": 113, "end": 123, "label": "DRUG"}, {"start": 78, "end": 87, "label": "ADE"}]}
{"text": "Hair loss associated with paroxetine treatment: a case report.", "entities": [{"start": 26, "end": 36, "label": "DRUG"}]}
{"text": "We report on a 37-year-old female who complained of moderate hair loss during paroxetine treatment.", "entities": [{"start": 78, "end": 88, "label": "DRUG"}, {"start": 61, "end": 70, "label": "ADE"}]}
{"text": "CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy.", "entities": []}
{"text": "METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.", "entities": [{"start": 30, "end": 37, "label": "DRUG"}, {"start": 131, "end": 138, "label": "DRUG"}, {"start": 65, "end": 74, "label": "ADE"}, {"start": 76, "end": 86, "label": "ADE"}, {"start": 103, "end": 111, "label": "ADE"}]}
{"text": "OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.", "entities": [{"start": 81, "end": 92, "label": "DRUG"}, {"start": 209, "end": 224, "label": "DRUG"}]}
{"text": "Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity.", "entities": [{"start": 105, "end": 131, "label": "ADE"}]}
{"text": "Protamine allergy as a complication of insulin hypersensitivity: A case report.", "entities": []}
{"text": "She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives.", "entities": [{"start": 25, "end": 40, "label": "DRUG"}, {"start": 105, "end": 110, "label": "ADE"}]}
{"text": "The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.", "entities": [{"start": 99, "end": 102, "label": "DRUG"}, {"start": 143, "end": 158, "label": "DRUG"}, {"start": 30, "end": 39, "label": "ADE"}, {"start": 44, "end": 54, "label": "ADE"}]}
{"text": "A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.", "entities": [{"start": 86, "end": 97, "label": "DRUG"}]}
{"text": "An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.", "entities": [{"start": 72, "end": 83, "label": "DRUG"}]}
{"text": "Apparent central nervous system depression in infants after the use of topical brimonidine.", "entities": [{"start": 79, "end": 90, "label": "DRUG"}, {"start": 9, "end": 42, "label": "ADE"}]}
{"text": "CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants.", "entities": [{"start": 21, "end": 32, "label": "DRUG"}, {"start": 56, "end": 89, "label": "ADE"}]}
{"text": "PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant.", "entities": [{"start": 46, "end": 57, "label": "DRUG"}, {"start": 79, "end": 112, "label": "ADE"}, {"start": 117, "end": 133, "label": "ADE"}]}
{"text": "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.", "entities": [{"start": 126, "end": 137, "label": "DRUG"}, {"start": 143, "end": 174, "label": "ADE"}, {"start": 179, "end": 203, "label": "ADE"}]}
{"text": "Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.", "entities": [{"start": 42, "end": 53, "label": "DRUG"}]}
{"text": "Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.", "entities": [{"start": 53, "end": 65, "label": "DRUG"}]}
{"text": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.", "entities": [{"start": 84, "end": 96, "label": "DRUG"}, {"start": 42, "end": 65, "label": "ADE"}]}
{"text": "During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.", "entities": [{"start": 25, "end": 41, "label": "DRUG"}, {"start": 154, "end": 193, "label": "ADE"}]}
{"text": "A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.", "entities": [{"start": 165, "end": 176, "label": "DRUG"}, {"start": 34, "end": 39, "label": "ADE"}, {"start": 41, "end": 47, "label": "ADE"}, {"start": 49, "end": 56, "label": "ADE"}, {"start": 58, "end": 70, "label": "ADE"}, {"start": 72, "end": 94, "label": "ADE"}]}
{"text": "With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion.", "entities": [{"start": 140, "end": 151, "label": "DRUG"}, {"start": 85, "end": 123, "label": "ADE"}]}
{"text": "We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug.", "entities": [{"start": 77, "end": 81, "label": "DRUG"}, {"start": 171, "end": 196, "label": "ADE"}]}
{"text": "We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency.", "entities": [{"start": 119, "end": 123, "label": "DRUG"}, {"start": 59, "end": 89, "label": "ADE"}]}
{"text": "An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.", "entities": [{"start": 52, "end": 63, "label": "DRUG"}, {"start": 3, "end": 24, "label": "ADE"}]}
{"text": "The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.", "entities": [{"start": 19, "end": 30, "label": "DRUG"}, {"start": 46, "end": 62, "label": "ADE"}]}
{"text": "This is the first report of a possible association between an acute cardiovascular event and venlafaxine.", "entities": [{"start": 93, "end": 104, "label": "DRUG"}, {"start": 62, "end": 88, "label": "ADE"}]}
{"text": "We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment.", "entities": [{"start": 115, "end": 126, "label": "DRUG"}, {"start": 142, "end": 168, "label": "ADE"}]}
{"text": "Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?", "entities": [{"start": 9, "end": 35, "label": "DRUG"}, {"start": 36, "end": 47, "label": "ADE"}]}
{"text": "The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.", "entities": []}
{"text": "The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.", "entities": [{"start": 114, "end": 131, "label": "ADE"}, {"start": 133, "end": 152, "label": "ADE"}, {"start": 154, "end": 170, "label": "ADE"}, {"start": 172, "end": 188, "label": "ADE"}, {"start": 190, "end": 207, "label": "ADE"}, {"start": 209, "end": 222, "label": "ADE"}, {"start": 228, "end": 247, "label": "ADE"}, {"start": 258, "end": 276, "label": "ADE"}, {"start": 281, "end": 293, "label": "ADE"}]}
{"text": "We conclude that (a) cyclophosphamide is a human teratogen, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question.", "entities": [{"start": 21, "end": 37, "label": "DRUG"}]}
{"text": "In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels.", "entities": [{"start": 56, "end": 65, "label": "DRUG"}]}
{"text": "Paradoxical seizures in phenytoin toxicity.", "entities": [{"start": 24, "end": 33, "label": "DRUG"}]}
{"text": "We present three patients with paradoxical seizures; their serum phenytoin levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL.", "entities": [{"start": 65, "end": 74, "label": "DRUG"}, {"start": 31, "end": 51, "label": "ADE"}]}
{"text": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "entities": [{"start": 37, "end": 45, "label": "DRUG"}, {"start": 68, "end": 78, "label": "ADE"}]}
{"text": "Losartan-induced angioedema.", "entities": [{"start": 0, "end": 8, "label": "DRUG"}, {"start": 17, "end": 27, "label": "ADE"}]}
{"text": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "entities": [{"start": 58, "end": 66, "label": "DRUG"}, {"start": 31, "end": 41, "label": "ADE"}]}
{"text": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "entities": [{"start": 41, "end": 49, "label": "DRUG"}, {"start": 17, "end": 27, "label": "ADE"}]}
{"text": "We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis.", "entities": [{"start": 105, "end": 112, "label": "DRUG"}, {"start": 68, "end": 84, "label": "ADE"}]}
{"text": "Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.", "entities": [{"start": 0, "end": 7, "label": "DRUG"}, {"start": 16, "end": 32, "label": "ADE"}]}
{"text": "Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).", "entities": [{"start": 60, "end": 70, "label": "DRUG"}]}
{"text": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.", "entities": [{"start": 147, "end": 154, "label": "DRUG"}, {"start": 163, "end": 179, "label": "ADE"}]}
{"text": "We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).", "entities": [{"start": 155, "end": 165, "label": "DRUG"}, {"start": 86, "end": 111, "label": "ADE"}]}
{"text": "Taxane-induced glaucoma.", "entities": [{"start": 15, "end": 23, "label": "ADE"}]}
{"text": "We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer.", "entities": [{"start": 40, "end": 49, "label": "DRUG"}, {"start": 20, "end": 28, "label": "ADE"}]}
{"text": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.", "entities": [{"start": 34, "end": 56, "label": "DRUG"}]}
{"text": "We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).", "entities": [{"start": 82, "end": 98, "label": "DRUG"}, {"start": 103, "end": 121, "label": "DRUG"}, {"start": 20, "end": 43, "label": "ADE"}]}
